• Attracting early-stage private financing can be difficult for FOAK technologies because they require large infrastructure investments without a track record, creating a “bankability gap.”
• A few factors tend to separate FOAK deals that get financed from ones that stall.
• This is the kind of multilayer structuring problem Market Street Capital is built to help sponsors navigate, not as an energy-specific lender but as an independent advisor and structurer.

Every energy technology that eventually becomes “bankable” has to survive an awkward middle stage first, the point where the tech has been proven in a lab or pilot but hasn’t yet run at commercial scale long enough for lenders to trust it. These first-of-a-kind (“FOAK”) projects are demonstration- and deployment-stage projects being brought to final investment decision for the first time, without the operating history conventional lenders rely on. These projects can’t be financed like conventional infrastructure. There’s no historical performance data, technology risk is higher and it’s harder for lenders to feel comfortable. The fix isn’t a single loan or investor, but a layered capital stack, with each layer priced for a different piece of the risk. Helping sponsors assemble and negotiate that stack is where firms such as Market Street Capital come in, working across debt, equity and structuring as sponsors pursue a financing that lenders will support.

Conventional project finance works because lenders can underwrite predictable cash flows against proven technology backed by strong offtake. However, attracting early-stage private financing can be difficult for FOAK technologies because they require large infrastructure investments without a track record, creating a “bankability gap.” Performance guarantees are thin, construction costs are harder to pin down and counterparties are often unproven. The natural response from senior lenders is to pull back or shrink their check size, which makes equity more expensive and pushes sponsors toward hybrid capital to bridge the gap.

Senior debt remains the cheapest capital available, sitting first in line and wanting long-dated, contracted cash flow. For FOAK deals, senior debt typically covers a smaller share of total cost than in conventional projects, and senior lenders often need support from programs such as the U.S. Department of Energy loan programs administered under Title 17 (program naming and structure as of August 2026), export credit agencies or completion guarantees before they’ll commit. 

Mezzanine debt can fill the gap between what senior lenders will underwrite and what sponsor equity can fund alone. Mezzanine sits between senior debt and equity, carries a higher coupon and is typically structured as subordinated debt with warrants or other equity features; it is flexible, but it requires careful intercreditor negotiation. 

Tax equity monetizes incentives such as the Investment Tax Credit (“ITC”) or Production Tax Credit (“PTC”) along with accelerated depreciation. For example, according to Norton Rose Fulbright, about 80% of solar tax equity deals use a “partnership flip” structure, which typically raises 35% of project value (plus or minus 5%), alongside two other common structures: inverted leases and sale-leasebacks. Since the Inflation Reduction Act, sponsors have a further option: Section 6418 of the IRA allows an eligible taxpayer to transfer some or all of an eligible tax credit directly to an unrelated buyer in exchange for cash, giving sponsors an alternative to the more complex legacy tax equity structures.

In addition, offtake-backed structures, or power purchase agreements (“PPAs”), tolling agreements and product offtake contracts, de-risk revenue. An offtake agreement is a contract between a power producer and a purchaser for the future output of a project, providing revenue certainty that is crucial for securing financing. PPAs can be physical, with actual delivery of power, or financial hedges where a creditworthy buyer provides guaranteed offtake in exchange for cost predictability, without taking physical delivery. Either structure can be used to anchor project financing. 

Sponsor/common equity and government co-investment sit at the bottom of the stack, absorbing first losses. Programs such as the DOE’s Energy Dominance Financing (Section 1706) program, which the DOE describes as guaranteeing loans to projects that add energy to the grid or enhance reliability (program guidance as revised May 2026), often function as much as a credibility signal to private lenders as a source of capital itself.

Layering five or more capital sources together means the real work isn’t just sourcing money. Rather, it’s sequencing it: Waterfall priority, covenant stacking and intercreditor agreements across senior debt, mezzanine, tax equity and offtake-linked capital all have to be negotiated so no single provider is left exposed to risk it didn’t sign up for.

A few factors tend to separate FOAK deals that get financed from ones that stall. Those factors can include creditworthy offtake counterparties, independent technical due diligence that validates performance claims, or completion and performance guarantees from sponsors or technology providers. Other factors could include risk allocated so no single capital source bears the technology risk alone and government co-investment that signals to private lenders the diligence has already been done.

This is the kind of multilayer structuring problem Market Street Capital is built to help sponsors navigate, not as an energy-specific lender but as an independent advisor and structurer. Through its Debt Capital Markets & Specialty Lending practice, the firm works on senior debt, unitranche and mezzanine structuring, and its private equity capital-raising capabilities extend that reach to the equity side of a deal. Market Street maintains a syndication network of more than 8,000 investor, family office, venture capital and bank contacts to date, which it uses to identify potential lenders and equity partners; network size does not indicate that any investor will participate in a given transaction. Its focus on designing facilities, negotiating intercreditor terms and preserving sponsor optionality maps directly onto the complexity of stacking senior debt, mezzanine and equity together.

FOAK financing is won or lost on structuring, not just capital availability. Sponsors typically need an adviser who can coordinate across five or more capital providers. That coordination role is the focus of Market Street’s middle-market advisory work.

For more information about the company, visit www.MarketStreetCP.com.

NOTE TO INVESTORS: The latest news and updates relating to Market Street are available in the company’s newsroom at https://ibn.fm/MarketSt

Disclosures

This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Any such offer may be made only pursuant to definitive offering materials and applicable transaction documents.

Nothing in this article is tax, legal or accounting advice. Readers should consult their own advisers.

Market data and third-party information are from sources believed to be reliable but have not been independently verified. No representation is made as to accuracy or completeness. Statements about financing structures are general in nature; no financing outcome can be assured.

Broker-dealer services are provided by Pickwick Capital Partners, LLC, Member FINRA/SIPC.

• SS Innovations, developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, up 39.4% year over year.
• First-half revenue reached $25.0 million, a 65.6% increase from the same period in 2025.
• The company’s SSi Mantra installations rose 30.4% to 30 systems during the quarter.
• The installed base reached 224 SSi Mantra systems across 12 countries, with 12,272 cumulative surgeries performed.
• U.S. and European regulatory milestones could become important catalysts, with the company targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026.
• The company’s telesurgery achievements are extending the clinical profile of SSi Mantra, while system installations remain the primary commercial growth driver.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, delivered another quarter of rapid top-line growth as demand for its SSi Mantra surgical robotic system continued to expand. The company reported second-quarter 2026 revenue of $13.9 million, an increase of 39.4% from $10.0 million a year earlier. Gross profit increased 20.0% to $7.1 million, although gross margin declined to 50.9% from 59.1% in the year-earlier quarter (https://ibn.fm/8BHJn).

The stronger comparison comes over the first six months of the year. Revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025. Gross profit increased 77.5% to $12.4 million, while first-half gross margin improved to 49.6% from 46.3%.

Additionally, SS Innovations installed 30 SSi Mantra systems during the second quarter, compared with 23 in the same period last year. For the first half, installations reached 56, versus 38 in the first half of 2025, representing growth of 47.4%. That brought the cumulative installed base to 224 systems across 12 countries as of June 30. The systems had been used in 12,272 surgeries, including 175 telesurgeries, 637 cardiac procedures, and 222 pediatric procedures.

The SSi Mantra is a modular system with three to five robotic arms, an ergonomic surgeon console, a 3D 4K display and instruments designed for procedures ranging from urology and gynecology to cardiac and pediatric surgery. That breadth matters because robotic surgery is not a single-procedure market. A system capable of supporting multiple specialties can potentially increase utilization at hospitals while creating additional demand for instruments and related services.

SS Innovations has also been using clinical training and telesurgery to expand the system’s capabilities and visibility. In April, the company hosted the Global Multi-Specialty Robotic Surgery Conference in New Delhi, which it said attracted more than 1,600 in-person attendees and 1,800 virtual participants from 19 countries.

In May, surgeons completed a telesurgery between Australia and India using SSi Mantra. In June, the company announced a robotic-assisted cardiac procedure conducted between Guyana and India across approximately 12,500 miles of fiber-network distance.

Then, after the quarter ended, SS Innovations reported another milestone. On July 29, surgeons led by Chief Executive Officer Dr. Sudhir Srivastava performed a robotic sleeve gastrectomy between Colombia and India across more than 13,600 miles of network distance. These procedures are notable from a technology-development standpoint, particularly because cardiac telesurgery remains an emerging application. 

SS Innovations has emphasized affordability and accessibility as part of its strategy, but the SSi Mantra is not simply being positioned as a lower-cost substitute for established robotic systems. Its modular architecture, multi-specialty applications, cardiac capabilities and telesurgery functionality represent areas in which SSII is seeking to establish its own technological identity.

The company has received outside recognition as well. In June, SS Innovations won the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, competing against nine other finalists. The company also graduated the first class from its specialized robotic cardiac surgery training program during the quarter.

Regulatory expansion remains another potentially important part of the investment thesis. SS Innovations said it expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. It is also pursuing European Union CE marking, which management believes could be obtained by the end of 2026.

Successful regulatory expansion would give SSII access to two of the world’s most important medical-device markets and provide a potential pathway for increasing the geographic diversity of future system sales.

Financially, the company entered the second half of 2026 with $13.6 million in cash and cash equivalents, excluding restricted cash, and no long-term debt. That balance sheet position provides an important backdrop as SS Innovations continues investing in commercialization, regulatory activities, manufacturing and international expansion.

With 56 systems installed during the first half, 224 systems already operating across 12 countries and revenue growth well ahead of the prior year, the company has established measurable commercial momentum. The potential U.S. and European regulatory milestones could determine how far that momentum can extend beyond its established Indian market.

“We remain enthusiastic about our ability to lead our foundational market of India, which is immense and growing, while expanding our global footprint in underserved countries and aiming for entry into the United States and European Union,” said Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations. “Our SSI Mantra has been engineered for precision, built to perform, and created to democratize access to advanced surgical robotic care—all underpinning our confidence in the future.”

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• Earth Science Tech seeks to implement a unified strategy aimed at maximizing shareholder value, resolving structural hurdles, and elevating corporate governance 
• The company will hold a virtual annual meeting on August 31, 2026, during which shareholders will vote on key initiatives that will position ETST for an uplisting to a higher-tier exchange, eliminate the structural barriers that hinder the infusion of institutional capital, and prevent stock dilution
• These initiatives are informed by extensive dialogue between shareholders and management leading to a consensus that the company’s current market valuation simply does not accurately reflect its financial success or future potential

The recent annual financial results posted by Earth Science Tech (OTC: ETST) reflect significant success and growth, which the diversified holding company attributes to an overarching focus on optimizing internal operations. The company, for instance, logged consecutive year-over-year increases in revenue and gross profit in the two years to March 31, 2026 (https://ibn.fm/GQzTa), and has maintained positive cash flow, establishing a strong operational and financial foundation. 

ETST’s management is nonetheless building on this foundation to expand the company’s focus toward the capital market and is keen on securing shareholder buy-in to implement a unified strategy aimed at resolving structural hurdles and elevating corporate governance. Specifically, the company is looking to position itself for an uplisting and is intent on eliminating the structural barriers that hinder the infusion of institutional capital.

The execution of this unified strategy hinges on four key initiatives that emerged from extensive dialogue with retail shareholders and institutional investors. (These initiatives will be on the voting agenda at an upcoming annual meeting.) The first initiative seeks to eliminate the existing dual-class voting structure, which dissuades institutional investors from buying into the company. Shareholders can authorize, by way of a vote, the Board’s independent Special Committee to negotiate the cash-only purchase and retirement of the CEO’s Series B Preferred Stock, which holds super-voting power.

Shareholders will also vote on an advisory recommendation to pursue a reverse stock split that will be implemented only if deemed necessary by the Board. The second initiative is aimed at enabling Earth Science Tech to achieve the minimum bid price required to uplist to a higher-tier exchange, such as Nasdaq, NYSE American, or OTCQX. Shareholders can also vote to stop the issuance of stock options, equity bonuses, or other stock-based incentives as executive compensation in favor of cash-centric remuneration. This third initiative is geared toward protecting equity by preventing dilution. The last initiative relates to standard governance matters.

“Our primary directive is to maximize value for our shareholders,” commented Giorgio R. Saumat, CEO and Chairman of the Board. “Over the last few years, we put our heads down to drive operational excellence. That hard work has resulted in consistent positive cash flow and allowed us to actively buy back our own stock, fortifying our balance sheet. However, having listened closely to the feedback from our investors and institutional partners, we agree that our current market valuation simply does not accurately reflect our financial success or future potential.”

Accordingly, the company’s proxy statement, filed with the SEC (https://ibn.fm/lf6ds), represents the company’s efforts to address shareholders’ concerns, protect their equity, and prepare for institutional growth. ETST invites all shareholders to participate in the vote, which is scheduled to be held during its virtual annual meeting on August 31, 2026. “We invite all shareholders to participate in this vote and join us in unlocking our true market value,” concluded Mr. Saumat.

For more information, visit the company’s website at www.EarthScienceTech.com. 

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST 

• Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027.
• FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group.
• In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing process that raises yield approximately 400%.

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between clinical validation and market adoption. Regentis Biomaterials (NYSE American: RGNT) is attempting exactly that, advancing its GelrinC(R) cartilage repair platform along a U.S. clinical track and a European commercial track and scaling of manufacturing at the same time.

The U.S. Program Approaches Its Defining Milestone

GelrinC is a cell-free, off-the-shelf hydrogel implant for focal articular cartilage defects in the knee. Rather than harvesting cells from the patient, expanding them in a laboratory and implanting them during a second surgery, GelrinC arrives ready to use and is implanted in a procedure lasting roughly 10 minutes. The hydrogel forms a temporary programmed matrix inside the defect, then erodes on a synchronized schedule as surrounding cells aggregate and form new tissue inward.

The pivotal SAGE study is enrolling 80 patients under an FDA-approved IDE protocol running across the U.S., Europe and Israel. More than half of the targeted 80 patients have been recruited and treated, with the study incorporating 24-month follow-up. The company reports no serious adverse events observed to date. Regentis is targeting completion of recruitment in the third quarter of 2026, with a premarket approval submission expected to begin at the end of 2027.

Completing enrollment would move the program out of patient recruitment and into data generation, the phase that produces the package a PMA filing rests on.

A Protocol Designed to Reduce Trial Risk

The study design merits attention on its own. FDA permitted a single-arm protocol using a historical microfracture control data package owned by Regentis and drawn from the TiGenix NV1 program, rather than requiring a concurrent randomized control arm. That design reduces the cost and variability associated with recruiting and managing a concurrent control cohort.

It also provides an early read on comparability. According to the company, the first 40 patients closely match the historical control group in baseline characteristics, an important consideration validating the comparability of the two populations.

The clinical foundation beneath that design came from a 56-patient Phase II study followed for up to five years in Northern Europe and Israel. Primary endpoints were met at 24 months, with approximately 100% greater KOOS pain and function improvement compared to microfracture and a mean MOCART imaging score of 88.8 out of 100, providing additional objective and quantitative evidence of quantity and quality of cartilage repair.

Europe Shifts from Approval to Adoption

Europe sits further along because GelrinC has already secured CE Mark approval. The focus there can therefore shift from obtaining initial authorization toward commercialization, surgeon adoption and distribution.

Hands-on surgeon training begins in the third quarter of 2026 at Humanitas Research Hospital in Milan, with additional sessions planned for other major European markets. Those sessions anchor a growing network of European Centers of Excellence intended to function as clinical hubs were experienced orthopedic surgeons train and support other physicians. The clinical site network behind that effort has expanded beyond Northern and Central Europe into Italy and Eastern Europe, adding sites in Pavia, Hamburg, Ljubljana, Timisoara and Belgrade.

On the commercial side, Regentis has been exploring regional distributors to map country priorities and working with European toll manufacturers on commercial sourcing.

Supply Built Ahead of Demand

Manufacturing is the piece that can stall a launch. In July, the European Notified Body approved the company’s next-generation solvent-free process for GelrinC, which Regentis says increases production yield by approximately 400%, or roughly fivefold, from the same manufacturing volume while lowering cost and improving occupational and environmental safety.

The timing may be as important as the magnitude of the improvement. Regentis can enter European commercialization using the higher-yield process.

Two Timelines, One Objective

The significance of the company’s current position lies in convergence rather than in any single announcement. In the United States, Regentis is progressing towards the enrollment milestone that opens the path toward a PMA filing. In Europe, approval is behind it and the remaining work is training, connecting with distributors and supply. Both tracks point at the same outcome: turning years of clinical development into a cartilage repair product that can be manufactured, sold and used on a scale.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. 

• Powermax Minerals is advancing four rare earth exploration projects across Canada and the U.S. as governments seek to reduce reliance on foreign supply chains.
• The company has begun its 2026 field program at the Cameron REE Project in British Columbia, focusing on refining targets identified through earlier geochemical and radiometric work.
• Atikokan in Ontario has produced district-scale REE anomalies, while the Pinard project is entering a Phase 1 exploration program designed to generate and rank targets.
• The Ogden Bear Lodge project gives Powermax exposure to a U.S. rare earth district that has attracted federal support and financing interest.
• The Powermax portfolio provides investors with exposure to the exploration stage of a critical-minerals market facing projected demand growth and a supply chain heavily concentrated in China.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects, is continuing exploration across its North American rare earth element portfolio as demand for critical minerals becomes increasingly linked to energy security and efforts to diversify supply chains.

The company most recently commenced its 2026 exploration program at the Cameron Rare Earth Element Project near Revelstoke, British Columbia. The field program is a follow up on anomalous results from previous stream sediment, soil and rock sampling and refine targets for potential trenching and drilling.

The Cameron exploration program combines geological mapping, prospecting, selective rock sampling, infill soil sampling, additional stream sediment work and ground radiometric surveys. Powermax plans to integrate those datasets into a target-ranking model that can guide subsequent exploration. Previous work at Cameron identified elevated light rare earth oxide, heavy rare earth oxide and total rare earth oxide values. The property also contains mapped pegmatites and historical thorium-uranium occurrences. Powermax cautions that the project remains at an early exploration stage and that geochemical or radiometric anomalies do not establish the presence of economically recoverable mineralization.

The Cameron work is part of a broader strategy. Powermax is building exposure across four projects located in established mining regions, with the objective of reducing reliance on any single exploration target.

The company’s Atikokan REE Project in northwestern Ontario covers 9,416 hectares across three claim blocks. The property sits along the White Otter–Dashwa corridor, where Powermax has identified REE-enriched granitic and pegmatitic systems.

Airborne magnetic and gamma-ray surveys, geological mapping and geochemical sampling conducted in 2025 produced Total Rare Earth Element values ranging from 254 parts per million to 1,947 ppm across Blocks B and C. An integrated interpretation identified a structural and geochemical corridor that the company is now using for surface validation and target ranking.

The Pinard Rare Earths Project provides another Ontario opportunity. Located approximately 70 kilometers north-northeast of Kapuskasing, the property comprises 255 contiguous claims covering 5,178 hectares. Pinard is situated within the Pinard Intrusive Rock Complex, an alkaline to peralkaline igneous system containing syenitic and granitic phases. Such geological environments can be associated with REE mineralization.

Powermax has outlined a Phase 1 program combining historical information with geological mapping, geochemical sampling, radiometric surveys and airborne geophysics. The immediate objective is to identify and prioritize targets for follow-up work.

In the United States, the company holds a 100% interest in the Ogden Bear Lodge Project in Crook County, Wyoming. The 184-hectare property consists of 22 lode claims and is prospective for neodymium-praseodymium oxide mineralization. The project’s location is particularly relevant to investors watching the development of domestic U.S. rare earth supply. Ogden Bear Lodge shares a border with Rare Element Resources’ Bear Lodge Critical Rare Earth Project, which has received $24.2 million in support from the U.S. Department of Energy and a non-binding letter of interest from the Export-Import Bank of the United States for up to $553 million in debt financing.

The backdrop for Powermax’s exploration strategy is a rare earth market undergoing structural change. McKinsey estimates global REE demand could rise from about 59,000 tonnes in 2022 to 176,000 tonnes by 2035, driven in part by electric vehicles and wind power (https://ibn.fm/1hLaV). 

At the same time, the supply chain remains highly concentrated. China accounts for roughly 60% of global rare earth mining and about 90% of processing capacity, according to reporting by the BBC. That concentration has pushed governments in North America to support domestic exploration, processing and supply-chain development. The U.S. has been using federal programs to support critical-mineral projects, while Canada’s Critical Minerals Infrastructure Fund is intended to facilitate investment in infrastructure required by the sector. For Powermax, the policy environment creates a favorable backdrop. With rare earth demand expected to grow and governments seeking alternatives to concentrated overseas supply chains, Powermax is positioning its portfolio within a market where strategic importance is rising. 

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

• A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company’s intellectual property footprint into one of the world’s largest cartilage-repair markets.
• The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale.
• The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial.

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual property becomes just as important as clinical performance.

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, a cell-free hydrogel for knee cartilage repair delivered in a single procedure of about 10 minutes, with no cell harvesting or laboratory processing. On July 20, the company strengthened its position in one of the world’s largest cartilage-repair markets.

Japan: A Substantial and Growing Market for Cartilage Repair

Aging is expanding the patient pool for the cartilage-repair opportunity across every developed market, and Asia is growing fastest. Japan is a marquee example. Published research estimates roughly 25 million people over the age of 40 in Japan have radiographic knee osteoarthritis, including about 8 million with symptomatic disease, while independent market research projects the country’s cartilage-repair market will approach $289 million by 2030. Demand is not the question. The competitive question is who can serve the market on a scale. For regenerative medicine companies, geographic expansion requires manufacturing systems capable of supporting broad adoption.

For an Off-the-Shelf Product, the Process Is the Moat

That question turns on manufacturing. Many current cartilage repair approaches rely on cell-based procedures, but their multi-step model, with tissue harvested from the patient, expanded in a laboratory over weeks, then reimplanted, is expensive and difficult to scale, which can involve significant cost and operational complexity. GelrinC is designed around the opposite model: a ready-to-use liquid formulation produced without organic solvents and intended to deliver a simpler, lower-cost alternative to cell-based procedures.

The differentiator is the manufacturing platform behind that formulation. Regentis has developed a solvent-free manufacturing method that raises yield 5-fold, simplifies production, and is built to scale for commercial supply. In a category where an off-the-shelf product only succeeds if it can be manufactured consistently and economically at volume, production capability is a critical commercial differentiator.

IP Protecting a Manufacturing Advantage in a Major Market

The July 20 announcement reinforces that strategy. The Japan Patent Office issued a Notice of Allowance for Regentis’s application covering the solvent-free protein-polymer conjugate compositions and manufacturing methods behind GelrinC’s ready-to-use formulation. Securing patent protection for that process in Japan helps protect the manufacturing approach that supports GelrinC’s scalability and commercial objectives.

“Our proprietary manufacturing technology is a key competitive advantage for GelrinC,” said Ehud Geller, CEO and Executive Chairman of Regentis. The allowance further expands a worldwide portfolio of nearly 30 granted patents spanning product composition, surgical technique, and manufacturing methods, with additional applications pending.

From Approval Toward Commercialization

Regentis is moving from clinical proof toward commercial reality. GelrinC holds CE Mark approval in the European Union, where commercialization efforts are beginning in 2026, and its pivotal U.S. trial has passed 50% enrollment, with a premarket approval preparation targeted for the end of 2027. Beyond knee cartilage repair, the Gelrin platform is also being evaluated for additional applications, including smaller joints and earlier-stage osteoarthritis indications.

The clinical case for GelrinC has been building for years through published imaging and outcome data. The Japanese patent allowance highlights that transforming clinical progress into a global commercial product depends not only on therapeutic performance, but also on manufacturing capability and intellectual property protection. While regulatory approval and clinical outcomes remain the ultimate determinants of success, Regentis is building the operational foundation needed to compete in the expanding cartilage-repair market.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

• Real-world asset activity is moving beyond proof-of-concept deployments, with tokenized funds, Treasuries, private credit and commodities increasingly being used across on-chain financial markets.
• As institutional participation grows, the next challenge is building secure, scalable and risk-mitigated infrastructure capable of supporting tokenized assets in production.
• MindWave Innovations is positioning MindChain, an insured Ethereum-compatible Layer 2, to support real-world asset applications alongside insurance, AdTech and ClimateTech through dedicated industry-specific subnetworks.

For years, the promise of blockchain in financial markets centered on putting traditional assets on chain. Now, the harder question is emerging: what infrastructure is needed to make those assets useful on an institutional scale?

Tokenized real-world assets, or RWAs, are beginning to move beyond experimentation. Tokenized Treasury funds, private credit products, commodities and other traditional financial instruments are increasingly being used as collateral, traded through on-chain venues and integrated into decentralized financial applications. A recent CoinShares report found that RWA deposits across lending platforms and decentralized exchanges more than tripled year over year, reaching $7.4 billion in the second quarter of 2026, while RWA spot trading volumes increased approximately 220%.

That growth suggests the opportunity is becoming less about whether traditional assets can be tokenized and more about whether the underlying infrastructure is ready for production.

The Next RWA Challenge Is Infrastructure

Tokenization can make traditional assets more programmable, divisible and accessible, but creating a digital representation of an asset is only one piece of the equation. Institutional adoption also requires reliable settlement, predictable transaction costs, security, governance and mechanisms for managing operational and financial risk.

The market remains relatively concentrated, with tokenized Treasury and multi-strategy funds and private credit accounting for much of current RWA activity. Ethereum hosted close to 70% of RWA deposits tracked by CoinShares, while institutional products can carry average wallet balances in the tens of millions of dollars. As the market expands, infrastructure will be needed to accommodate institutions accustomed to stringent standards around security, reporting, governance and risk management.

That is the market MindWave Innovations (NYSE American: APUS) is targeting with its broader institutional digital-finance strategy.

Building Rails for Tokenized Assets

MindWave is developing MindChain, an Ethereum Virtual Machine-compatible Layer 2 network that the company describes as the world’s first fully insured blockchain. Scheduled for launch in October 2026, MindChain will operate through its own sequencer and validator set while settling transactions on Ethereum.

Rather than treating tokenization as a standalone application, MindChain is being designed around industry-specific use cases. The network is expected to support dedicated subnetworks for real-world assets, insurance, AdTech and ClimateTech, with the initial RWA focus on real estate and commodities.

That structure could allow organizations to establish dedicated blockchain environments with defined operating parameters while remaining connected to the broader MindWave ecosystem. For tokenized assets, such infrastructure could support applications involving ownership, settlement, liquidity and other financial functions.

Risk Mitigation for Institutional Adoption

As more capital moves on-chain, security and risk management become increasingly important. Infrastructure failures, smart-contract vulnerabilities and operational errors can carry greater consequences when significant financial assets are involved.

MindChain’s insurance component is designed to address part of that challenge. Rather than replacing blockchain security measures, the insurance-oriented architecture adds another layer of risk mitigation around a network intended to support financial applications.

That distinction could become increasingly relevant as tokenization moves from pilot programs toward larger-scale deployment. Institutions evaluating blockchain infrastructure need to consider not only whether transactions can be processed, but also how assets are protected, how risks are managed and how the infrastructure performs at scale.

From RWA Issuance to RWA Utility

The evolution of tokenized assets may ultimately depend less on how many assets are issued and more on what those assets can do.

RWA activity is already expanding beyond passive ownership. Tokenized assets are being used across lending, spot trading and other financial applications, while tokenized Treasury products have emerged as forms of on-chain collateral. If that trend continues, the networks supporting RWAs will need to provide more than basic transaction processing. They will need predictable economics, interoperability and flexibility to support different requirements across asset classes.

MindChain’s subnet model is designed around that concept. Its initial focus on real estate and commodities provides a tangible starting point, while the broader network is intended to support multiple industries through dedicated environments.

The Road to MindChain

Recent milestones provide a defined sequence for MindWave’s strategy. NILA, the company’s ecosystem token, became available to U.S. users through Webot on Aug. 3 ahead of the planned MindChain migration. Once the network launches, NILA is expected to become the native asset used for gas, steaking and network security.

MindWave has outlined an August-to-September test net period for community and developer onboarding, with a third-party security audit underway, followed by the expected October 2026 main net launch. The rollout is also expected to include a migration portal, block explorer and bridge interface.

These milestones begin turning MindWave’s blockchain strategy from a conceptual platform into an operating infrastructure layer.

The Institutional Tokenization Opportunity

Real-world asset tokenization remains an early-stage market, representing only a fraction of the value contained in traditional financial markets. Adoption is also concentrated across a relatively small number of products and networks. But as financial institutions move from testing tokenization toward incorporating tokenized assets into lending, trading, collateral and treasury strategies, demand could increasingly shift toward infrastructure designed for reliability, interoperability and risk management.

MindWave is positioning MindChain around that transition. By combining an Ethereum-compatible Layer 2 with dedicated industry subnetworks and insurance-oriented architecture, the company is seeking to provide infrastructure for a market moving from token creation toward real-world utility.

MindChain’s ability to attract users, developers, issuers and institutional capital will ultimately determine the success of the strategy. But as tokenized real-world assets move closer to becoming an established component of digital financial markets, the infrastructure supporting those assets may become just as important as the tokens themselves.

For more information, visit the company’s website at www.MindWaveDAO.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity.
• That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
• Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery.

Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.

For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity (“PIRA”).

PIRA can occur at any point in the disease, even in early relapsing-remitting MS, and it challenges the old idea that relapsing and progressive MS are separate categories. Instead, evidence increasingly suggests MS behaves more like a continuum, with progressive biology present from the earliest stages of disease. As highly effective therapies have gotten better at stopping relapses, PIRA has become a larger share of the disability picture, since it keeps advancing even when relapse-based measures look calm.

That shift has forced researchers to look at what is actually driving PIRA. An important contributor is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. These are areas of demyelinated tissue surrounded by a rim of activated microglia and macrophages, often carrying iron, sitting behind a largely intact blood brain barrier. Unlike the acute inflammation behind a relapse, this activity is quiet and sustained, which is why researchers describe it as smoldering.

These lesions are not just a side observation. Their presence is linked to worse long-term prognosis and to the transition from relapsing to progressive disease, and they are associated with impaired remyelination and ongoing tissue injury. Because this inflammatory activity is compartmentalized within the central nervous system (“CNS”) behind a relatively intact blood-brain barrier, it may be less effectively modulated by therapies that primarily target peripheral immune activity.

This is why microglial activation and compartmentalized CNS inflammation have become such active areas of research. Persistent innate immune activation at the edge of these lesions appears to sustain tissue injury even when standard MRI and relapse measures look stable. Some researchers are now pushing for chronic active lesion measurements to be built directly into clinical trials, since conventional relapse-based and MRI endpoints may miss this slow-burning damage entirely.

The result is a research landscape that increasingly values confirmed disability progression, PIRA-specific endpoints and imaging of chronic active lesions alongside, or instead of, plain relapse counts. It also raises a strategic question for drug developers: a therapy that only quiets peripheral immune activity may leave the CNS’s own compartmentalized inflammation untouched.

Quantum BioPharma’s approach to Lucid-MS reflects that reasoning. Rather than broadly suppressing the immune system, the compound is designed to inhibit myelin degradation, preserve myelin and support functional recovery, aiming at the tissue-level damage rather than only the immune trigger behind a relapse. That distinction matters in a field where the most stubborn source of disability may not be stopped by immune suppression alone. 

The company has also been developing tools to actually observe what is happening to myelin in real time. In June 2025, Quantum BioPharma and researchers at Massachusetts General Hospital scanned the first person with MS as part of a joint study validating a PET imaging technique for myelin integrity. The tracer involved was previously shown to be highly sensitive to demyelinated lesions in earlier animal and human studies. Tools like this could eventually help track chronic, low-grade myelin damage more directly than relapse counts or standard MRI scans currently allow.

In addition, Quantum BioPharma just received clearance to begin a phase 2 trial of Lucid-MS on patients with MS, following phase 1 studies that reported a favorable safety profile in healthy volunteers. The filing included data on pharmacology, toxicology and manufacturing quality, moving the program toward human efficacy testing for the very first time.  

Lucid-MS remains an early-stage program, with its evidence to date coming from preclinical models rather than controlled human trials. But its underlying premise, that meaningful progress in MS depends on addressing tissue-level damage and not just circulating immune cells, lines up with where much of the field’s research attention is now headed. As disability progression takes center stage in how new MS therapies are judged, programs built around myelin protection and chronic CNS inflammation are likely to draw closer scrutiny, and Quantum BioPharma’s early work sits directly in that space.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• Software can be deployed across thousands of existing aircraft without redesigning the airframe, creating a far larger addressable market than hardware.
• Registration as an AUKUS authorized user gives SPARC AI a permit-free route into U.S. and U.K. defense supply chains.
• Overwatch’s subscription model allows each new connected drone to expand recurring software revenue without requiring additional manufacturing capacity.

For decades, military advantage came from building better aircraft. Today’s battlefield increasingly rewards something different: making inexpensive aircraft smarter. As drones become cheaper and more disposable, software is becoming the primary source of military advantage. A single guided munition can cost more than a hundred small quadcopters, and the conflicts of the past three years have shown that a hundred quadcopters often accomplish more.

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) is built for that shift, delivering capability through software rather than additional hardware. That distinction is the heart of the investment case.

Why Cheap Drones Go Blind

Cheap aircraft are fragile in one specific way. They depend on satellite navigation, and satellite navigation is the first thing a capable adversary takes away. When a small drone loses GPS to jamming or spoofing, it falls back on an internal inertial measurement unit. Low-cost commercial IMUs accumulate error rapidly, and that compounding error, known as inertial drift, renders targeting data unusable within minutes. The aircraft may continue flying, but it gradually loses confidence in its own position, and, by extension, the location of anything it is trying to observe or target.

The conventional remedy is more equipment: a laser rangefinder, a radar module, a military-grade IMU. Each additional component increases weight, power consumption and cost onto a platform whose value proposition is being cheap enough to expend. Hardening an attritable drone with hardware makes it less attritable.

Software Becomes the Payload

SPARC AI attacks the drift itself. Its Overwatch platform runs machine learning models that identify and correct IMU noise and sensor bias before errors compound. From that stabilized position, the software calculates the ground coordinates of an observed target using the aircraft’s corrected pose, heading and pitch, converting ordinary optics into a precision instrument. Rather than relying on image-recognition databases, it uses line-of-sight mathematics, allowing it to operate over unmapped, smoky or rapidly changing terrain where trained models often struggle. Because the system operates passively, it emits no signals that can be detected or jammed.

The commercial logic follows the technical one. As drone hardware becomes increasingly standardized, differentiation shifts toward the software operating those platforms. Software can be deployed across thousands of existing platforms without redesigning the airframe, creating a much larger addressable market and greater operating leverage than hardware alone. SPARC AI has completed 15 years of research and development behind the approach and holds registered patents in seven countries, including the United States.

Embedding Into Fleets Others Build

Rather than manufacturing drones itself, SPARC AI embeds its software into platforms others already build. Its software development kit integrates with PX4 and ArduPilot, the dominant open-source flight ecosystems, giving manufacturers and developers a straightforward path to add GPS-denied navigation and targeting capabilities to existing fleets. Overwatch is also validated on the Parrot ANAFI GOV/MIL, a U.S.-built airframe on the Blue UAS Cleared List.

Commercial traction is beginning to build alongside product development. In May 2026, SPARC AI announced a partnership with U.S. defense contractor Rate Manufacturing to integrate Overwatch into its Model-F multi-mission drone systems unveiled at SOF Week in Tampa. A preferred reseller agreement with Precision Technic Defence Group extends distribution across Australia, Europe and the United States. The company has also established a permanent engineering presence in Ukraine, working alongside frontline drone manufacturers where electronic warfare is among the most demanding in the world and rapid product iteration is essential.

The AUKUS Unlock

On June 22, 2026, the Australian government registered SPARC AI as an authorized user under the AUKUS license-free environment established through the Defense Trade Controls Amendment Act 2024. Registration gives the company a permit-free route, potentially reducing administrative barriers to collaboration with eligible defense organizations in the United States and United Kingdom. 

Revenue That Scales with the Fleet

Defense contractors traditionally earn revenue by selling hardware one platform at a time. SPARC AI is pursuing a software model instead. The company charges an annual subscription for each connected device, meaning every additional drone running Overwatch becomes recurring revenue rather than another manufacturing project. Management has articulated an ambitious long-term objective: connect one million devices to the platform. Every new hardware partner has the potential to expand that installed base without requiring SPARC AI to manufacture a single aircraft. Separately, the company maintains a relatively tight capital structure, with approximately 19.3 million shares outstanding and insiders owning roughly 40%.

As military organizations increasingly field larger numbers of lower-cost autonomous systems, competitive advantage may depend less on who manufactures the airframe and more on who provides the intelligence that enables those platforms to operate effectively. SPARC AI is positioning Overwatch to become part of that software layer, allowing existing drone fleets to navigate, target and execute missions with greater resilience in GPS-denied environments.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• The forces underpinning gold’s recent strength are structural rather than momentary, even as the price itself has been volatile.
• All four of Lahontan’s properties sit within the Walker Lane trend and are located entirely within the United States.
• “This outstanding drill intercept, which includes some of the highest gold grades drilled to date within the Central Calvada deposit, reinforces the importance of the Calvada resource to the Santa Fe Mine project,” notes company exec.

Gold’s recent strength has increasingly been driven by structural demand rather than short-term speculation, and 2026 has provided investors with no shortage of reasons to seek safe-haven assets. Amid that backdrop sits Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF), a Canadian mineral exploration company that, through its U.S. subsidiaries, owns four top-tier gold and silver exploration properties in the Walker Lane trend of Nevada, anchored by its flagship Santa Fe Mine Project. The company is currently advancing Santa Fe toward a construction decision while running an active drilling campaign designed to define low-cost, near-term sources of gold and silver production.

Although gold experienced meaningful price swings during the first half of 2026, the World Gold Council concluded that geopolitical tensions, central bank buying and sustained investor demand continued to support the broader market despite elevated volatility.

For developers, that distinction matters because a stronger long-term pricing environment can improve project economics, financing options and investment interest. Central bank accumulation, particularly from emerging markets, has been a defining feature of that structural demand. Goldman Sachs analysts said in May 2026 that they now expect central banks to average around 60 tonnes per month through 2026, supported by continued diversification demand amid geopolitical uncertainty. Per data compiled by Discovery Alert, Poland has been the most aggressive single buyer, leading 2026 accumulation with 64 tonnes through May, while China, Uzbekistan and Kazakhstan have also been consistent purchasers. That accumulation has coincided with a broader shift in reserve composition, with gold now representing a larger share of global central bank reserves than U.S. Treasuries for the first time since 1996.

This sovereign buying does more than support a price floor; it changes the character of gold demand itself. Central banks buy for policy reasons tied to sanctions risk, currency diversification and reserve credibility rather than short-term trading conviction, which makes their purchases comparatively insensitive to price swings.

That dynamic was visible in the first quarter of 2026. Despite a pullback in spot prices, analysis found that central banks globally added a net 244 tonnes of gold to their reserves, a 17% increase from the previous quarter, while bar and coin demand from individual and institutional investors jumped 42% to 474 tonnes, the second-highest quarterly total on record. That combination, official accumulation continuing through weakness while private investors buy the dips, is the kind of two-sided support that has historically been difficult to sustain for gold and helps explain why Western investors have shown renewed willingness to add exposure on pullbacks rather than wait for a deeper correction.

For gold producers and developers, this environment has translated into unusually strong free cash flow. This gives many miners room to fund growth internally, return capital to shareholders through buybacks and dividends, and reduce reliance on dilutive equity financing. But not every gold company benefits equally from a rising price environment. Jurisdictional risk remains one of the biggest swing factors in how the market values an ounce in the ground, and developers with politically stable, well-permitted assets tend to command a premium over peers exposed to nationalization risk, currency controls, or unpredictable permitting regimes overseas.

This is where Lahontan’s Nevada-based portfolio stands out. All four of the company’s properties sit within the Walker Lane trend and are located entirely within the United States. Nevada has repeatedly ranked as a top jurisdiction globally for mining investment and received the highest policy perception index score of any jurisdiction, reflecting favorable views on permitting, taxation, regulatory clarity and overall governance. The state has also ranked consistently in the top 10 over the last 11 surveys. For developers competing for investment capital, operating in a stable mining jurisdiction can be as important as the quality of the deposit itself.

Santa Fe’s development strategy is progressing on multiple fronts. Alongside permitting activities, Lahontan continues expanding and refining the resource through targeted drilling designed to improve mine planning while identifying additional near-surface oxide mineralization.

The company’s latest results from Central Calvada illustrate that strategy. A drill hole originally designed to collect geotechnical information for mine permitting also intersected a significant interval of oxide gold mineralization. It intersected 30.8 meters of oxide mineralization grading 0.93 g/t gold equivalent near the base of the current resource pit shell, including a rich 10.7-meter section grading 2.18 g/t gold equivalent. Two additional holes drilled nearby, at the south end of the Slab open pit, also hit gold-bearing rock at surface. Those intersected 15.2 meters grading 0.40 g/t gold equivalent and 9.1 meters grading 0.22 g/t gold equivalent.

“This outstanding drill intercept, which includes some of the highest gold grades drilled to date within the Central Calvada deposit, reinforces the importance of the Calvada resource to the Santa Fe Mine project,” said Lahontan founder, chair, and CEO Kimberly Ann. “Once again, a drill hole originally planned to collect geotechnical data, in support of mine permitting, was carefully designed by our team to also intersect the core of the Central Calvada gold deposit, delivering excellent gold grades.

More recently, Lahontan reported one of the highest-grade intercepts encountered during the current campaign, returning 12.2 meters grading 9.74 g/t gold equivalent within a broader mineralized interval. Management said the results continue to demonstrate the potential for higher-grade zones within the Santa Fe system while supporting ongoing resource refinement and future mine planning.

Separately, a sonic drilling program targeting historic heap leach pads and stockpiles left behind by a previous operator has pointed to a lower-cost reprocessing opportunity. Results showed an average grade of 2.3 g/t gold equivalent across the first three sonic drill holes in a historic low-grade stockpile, including a standout intercept of 9.9 meters grading 2.40 g/t gold and 50.7 g/t silver. Preliminary metallurgical testing also supported the reprocessing concept, indicating that a meaningful portion of the contained gold is amenable to conventional heap-leach recovery.

Beyond the core Santa Fe deposit, the nearby West Santa Fe project offers additional exploration upside. Management believes the project could eventually provide supplemental feed to the planned processing infrastructure, potentially extending mine life while leveraging the same operating platform.

Taken together, Lahontan’s recent progress illustrates how the company is advancing Santa Fe on multiple fronts simultaneously. Continued drilling, permitting work, resource expansion and evaluation of historic stockpiles all contribute to a strategy focused on building a scalable Nevada gold operation. If structural demand continues supporting gold prices, developers capable of efficiently advancing low-cost projects in premier mining jurisdictions may be well positioned as the next generation of North American gold mines moves toward production.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF